ASH 2020 | Zanubrutinib for ibrutinib/acalabrutinib intolerant R/R B-cell malignancies
Ian Flinn, MD, PhD, Tennessee Oncology, Nashville, TN, gives an update on a Phase II study (NCT04116437) investigating the safety and efficacy of the Bruton’s tyrosine kinase inhibitor (BTKi) zanubrutinib in patients with relapsed/refractory chronic B-cell malignancies, including lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), who have become intolerant to prior ibrutinib and/or acalabrutinib therapy. Adverse events commonly lead to discontinuation of ibrutinib and acalabrutinib, and as they are thought to be related to off-target effects, zanubrutinib has been developed with enhanced selectivity. So far, the study has found that zanubrutinib demonstrated efficacy and tolerability in CLL/SLL patients who were intolerant to previous BTKi therapies, with most previously reported adverse events not recurring with zanubrutinib use. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Consultancy: AbbVie, AstraZeneca, BeiGene, Genentech, Gilead Sciences, Great Point Partners, Iksuda Therapeutics, Janssen, Juno Therapeutics, Kite Pharma, MorphoSys, Nurix Therapeutics, Pharmacyclics, Roche, Seattle Genetics, Takeda, TG Therapeutics, Unum Therapeutics, Verastem, Yingli Pharmaceuticals
Research Grants: AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Calithera Biosciences, Celgene, Constellation Pharmaceuticals, Curis, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, IGM Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Juno Therapeutics, Karyopharm Therapeutics, Kite Pharma, Loxo, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium Therapeutics, Triphase Research & Development Corp., Unum Therapeutics, Verastem.
All payments made to Sarah Cannon Research Institute, not to the physician
